Last Updated: November 17, 2026

SOLRIAMFETOL HYDROCHLORIDE Drug Patent Profile

« Back to Dashboard


When do Solriamfetol Hydrochloride patents expire, and what generic alternatives are available?

Solriamfetol Hydrochloride is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, and Hikma. and is included in three NDAs.

The generic ingredient in SOLRIAMFETOL HYDROCHLORIDE is solriamfetol hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the solriamfetol hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Solriamfetol Hydrochloride

A generic version of SOLRIAMFETOL HYDROCHLORIDE was approved as solriamfetol hydrochloride by ALKEM LABS LTD on June 17th, 2026.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for SOLRIAMFETOL HYDROCHLORIDE?
  • What are the global sales for SOLRIAMFETOL HYDROCHLORIDE?
  • What is Average Wholesale Price for SOLRIAMFETOL HYDROCHLORIDE?
Recent Clinical Trials for SOLRIAMFETOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, MontpellierPHASE2
Duke UniversityPHASE2
Axsome Therapeutics, Inc.Phase 2

See all SOLRIAMFETOL HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SOLRIAMFETOL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for SOLRIAMFETOL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SUNOSI Tablets solriamfetol hydrochloride 75 mg and 150 mg 211230 6 2023-06-20

US Patents and Regulatory Information for SOLRIAMFETOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkem Labs Ltd SOLRIAMFETOL HYDROCHLORIDE solriamfetol hydrochloride TABLET;ORAL 218722-001 Jun 17, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd SOLRIAMFETOL HYDROCHLORIDE solriamfetol hydrochloride TABLET;ORAL 218725-002 Oct 6, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Alkem Labs Ltd SOLRIAMFETOL HYDROCHLORIDE solriamfetol hydrochloride TABLET;ORAL 218722-002 Jun 17, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.